For further details see:
Corcept Therapeutics EPS beats by $0.06, misses on revenueFor further details see:
Corcept Therapeutics EPS beats by $0.06, misses on revenueMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
Market:
2024-05-02 17:30:02 ET Truist Financial analyst issues BUY recommendation for CORT on May 2, 2024 04:01PM ET. The previous analyst recommendation was Buy. CORT was trading at $25.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of th...